592 related articles for article (PubMed ID: 33340426)
21. Articular manifestations in patients with inflammatory bowel disease treated with vedolizumab.
Dupré A; Collins M; Nocturne G; Carbonnel F; Mariette X; Seror R
Rheumatology (Oxford); 2020 Nov; 59(11):3275-3283. PubMed ID: 32259251
[TBL] [Abstract][Full Text] [Related]
22. Superior Effectiveness of Tofacitinib Compared to Vedolizumab in Anti-TNF-experienced Ulcerative Colitis Patients: A Nationwide Dutch Registry Study.
Straatmijer T; Biemans VBC; Visschedijk M; Hoentjen F; de Vries A; van Bodegraven AA; Bodelier A; de Boer NKH; Dijkstra G; Festen N; Horjus C; Jansen JM; Jharap B; Mares W; van Schaik FDM; Ponsioen C; Romkens T; Srivastava N; van der Voorn MMPJA; West R; van der Woude J; Wolvers MDJ; Pierik M; van der Meulen-de Jong AE; Duijvestein M;
Clin Gastroenterol Hepatol; 2023 Jan; 21(1):182-191.e2. PubMed ID: 35644343
[TBL] [Abstract][Full Text] [Related]
23. Infectious risk of vedolizumab compared with other biological agents in the treatment of inflammatory bowel disease.
Innocenti T; Roselli J; Lynch EN; Apolito P; Parisio L; Bagnoli S; Macrì G; Rogai F; Tarocchi M; Milani S; Galli A; Milla M; Dragoni G
Eur J Gastroenterol Hepatol; 2021 Dec; 33(1S Suppl 1):e574-e579. PubMed ID: 35048649
[TBL] [Abstract][Full Text] [Related]
24. Biological treatment approach to inflammatory bowel disease is similar in academic and nonacademic centres - prime time for decentralisation of inflammatory bowel disease care?
Tepeš K; Hanžel J; Štubljar D; Strmšek K; Erjavec L; Supovec E; Jagodic Z; Končan M; Grosek J; Košir JA; Tomažič A; Kogovšek U; Norčič G; Šibli R; Žnidaršič M; Pačnik Vižintin T; Sodin B; Breznik J; Hribar VA; Ocepek A; Pernat Drobež C; Bukovnik N; Zafošnik A; Marušič T; Jurečič Brglez N; Denkovski M; Smrekar N; Novak G; Koželj M; Kurent T; Simonič J; Pintar Š; Štabuc B; Drobne D
Eur J Gastroenterol Hepatol; 2024 Jun; 36(6):728-734. PubMed ID: 38625825
[TBL] [Abstract][Full Text] [Related]
25. Comparative Outcomes and Safety of Vedolizumab vs Tumor Necrosis Factor Antagonists for Older Adults With Inflammatory Bowel Diseases.
Singh S; Iversen AT; Allin KH; Jess T
JAMA Netw Open; 2022 Sep; 5(9):e2234200. PubMed ID: 36178685
[TBL] [Abstract][Full Text] [Related]
26. Postoperative Outcomes in Vedolizumab-Treated Patients Undergoing Abdominal Operations for Inflammatory Bowel Disease.
Lightner AL; Raffals LE; Mathis KL; Cima RR; Tse CS; Pemberton JH; Dozois EJ; Loftus EV
J Crohns Colitis; 2017 Feb; 11(2):185-190. PubMed ID: 27543504
[TBL] [Abstract][Full Text] [Related]
27. Postoperative Outcomes in Vedolizumab-Treated Patients Undergoing Major Abdominal Operations for Inflammatory Bowel Disease: Retrospective Multicenter Cohort Study.
Lightner AL; Mathis KL; Tse CS; Pemberton JH; Shen B; Kochhar G; Singh A; Dulai PS; Eisenstein S; Sandborn WJ; Parry L; Stringfield S; Hudesman D; Remzi F; Loftus EV
Inflamm Bowel Dis; 2018 Mar; 24(4):871-876. PubMed ID: 29509927
[TBL] [Abstract][Full Text] [Related]
28. Comparative Risk of Serious Infections With Tumor Necrosis Factor α Antagonists vs Vedolizumab in Patients With Inflammatory Bowel Diseases.
Singh S; Heien HC; Herrin J; Dulai PS; Sangaralingham L; Shah ND; Sandborn WJ
Clin Gastroenterol Hepatol; 2022 Feb; 20(2):e74-e88. PubMed ID: 33640480
[TBL] [Abstract][Full Text] [Related]
29. Outcomes, dosing, and predictors of vedolizumab treatment in children with inflammatory bowel disease (VEDOKIDS): a prospective, multicentre cohort study.
Atia O; Shavit-Brunschwig Z; Mould DR; Stein R; Matar M; Aloi M; Ledder O; Focht G; Urlep D; Hyams J; Broide E; Weiss B; Levine J; Russell RK; Turner D
Lancet Gastroenterol Hepatol; 2023 Jan; 8(1):31-42. PubMed ID: 36306803
[TBL] [Abstract][Full Text] [Related]
30. Vedolizumab Therapy Is Associated with an Improvement in Sleep Quality and Mood in Inflammatory Bowel Diseases.
Stevens BW; Borren NZ; Velonias G; Conway G; Cleland T; Andrews E; Khalili H; Garber JG; Xavier RJ; Yajnik V; Ananthakrishnan AN
Dig Dis Sci; 2017 Jan; 62(1):197-206. PubMed ID: 27796768
[TBL] [Abstract][Full Text] [Related]
31. Multi-Center Experience of Vedolizumab Effectiveness in Pediatric Inflammatory Bowel Disease.
Singh N; Rabizadeh S; Jossen J; Pittman N; Check M; Hashemi G; Phan BL; Hyams JS; Dubinsky MC
Inflamm Bowel Dis; 2016 Sep; 22(9):2121-6. PubMed ID: 27542130
[TBL] [Abstract][Full Text] [Related]
32. Difficult-to-treat inflammatory bowel disease: Effectiveness and safety of 4th and 5th lines of treatment.
Caron B; Habert A; Bonsack O; Camara H; Jeanbert E; Parigi TL; Netter P; Danese S; Peyrin-Biroulet L
United European Gastroenterol J; 2024 Jun; 12(5):605-613. PubMed ID: 38594841
[TBL] [Abstract][Full Text] [Related]
33. Safety, efficacy and pharmacokinetics of vedolizumab in patients with simultaneous exposure to an anti-tumour necrosis factor.
Ben-Horin S; Ungar B; Kopylov U; Lahat A; Yavzori M; Fudim E; Picard O; Peled Y; Eliakim R; Del Tedesco E; Paul S; Roblin X
Aliment Pharmacol Ther; 2018 Apr; 47(8):1117-1125. PubMed ID: 29446098
[TBL] [Abstract][Full Text] [Related]
34. Vedolizumab Effectiveness and Safety Over the First Year of Use in an IBD Clinical Practice.
Vivio EE; Kanuri N; Gilbertsen JJ; Monroe K; Dey N; Chen CH; Gutierrez AM; Ciorba MA
J Crohns Colitis; 2016 Apr; 10(4):402-9. PubMed ID: 26681763
[TBL] [Abstract][Full Text] [Related]
35. Pharmacodynamic assessment of vedolizumab for the treatment of ulcerative colitis.
McLean LP; Cross RK
Expert Opin Drug Metab Toxicol; 2016 Jul; 12(7):833-42. PubMed ID: 27096357
[TBL] [Abstract][Full Text] [Related]
36. Vedolizumab use after failure of TNF-α antagonists in children and adolescents with inflammatory bowel disease.
Schneider AM; Weghuber D; Hetzer B; Entenmann A; Müller T; Zimmermann G; Schütz S; Huber WD; Pichler J
BMC Gastroenterol; 2018 Sep; 18(1):140. PubMed ID: 30219028
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists.
Feagan BG; Rubin DT; Danese S; Vermeire S; Abhyankar B; Sankoh S; James A; Smyth M
Clin Gastroenterol Hepatol; 2017 Feb; 15(2):229-239.e5. PubMed ID: 27639327
[TBL] [Abstract][Full Text] [Related]
38. Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry.
Chaparro M; Garre A; Ricart E; Iborra M; Mesonero F; Vera I; Riestra S; García-Sánchez V; Luisa De Castro M; Martin-Cardona A; Aldeguer X; Mínguez M; de-Acosta MB; Rivero M; Muñoz F; Andreu M; Bargalló A; González-Muñoza C; Pérez Calle JL; García-Sepulcre MF; Bermejo F; Huguet JM; Cabriada JL; Gutiérrez A; Mañosa M; Villoria A; Carbajo AY; Lorente R; García-López S; Piqueras M; Hinojosa E; Arajol C; Sicilia B; Conesa AM; Sainz E; Almela P; Llaó J; Roncero O; Camo P; Taxonera C; Domselaar MV; Pajares R; Legido J; Madrigal R; Lucendo AJ; Alcaín G; Doménech E; Gisbert JP;
Aliment Pharmacol Ther; 2018 Oct; 48(8):839-851. PubMed ID: 30281832
[TBL] [Abstract][Full Text] [Related]
39. [Current position on Vedolizumab for ulcerative colitis and Crohn's disease].
Schreiber S; Dignass AU; Hartmann H; Kruis W; Rogler G; Siegmund B; Stallmach A; Witte C; Bokemeyer B
Z Gastroenterol; 2015 Jun; 53(6):591-602. PubMed ID: 26016456
[TBL] [Abstract][Full Text] [Related]
40. The Use of Vedolizumab in Preventing Postoperative Recurrence of Crohn's Disease.
Yamada A; Komaki Y; Patel N; Komaki F; Pekow J; Dalal S; Cohen RD; Cannon L; Umanskiy K; Smith R; Hurst R; Hyman N; Rubin DT; Sakuraba A
Inflamm Bowel Dis; 2018 Feb; 24(3):502-509. PubMed ID: 29462385
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
